.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Acute Myeloid Leukemia: The Path to Personalized Medicine

EP. 1: Leukapheresis in AML

January 10th 2019

EP. 2: Updates on Chemotherapy Regimens in AML

January 10th 2019

EP. 3: High-Dose Anthracycline Therapy in AML

January 10th 2019

EP. 4: Venetoclax for AML

January 10th 2019

EP. 5: Considerations for Treating With Venetoclax in AML

January 10th 2019

EP. 6: Glasdegib for AML

January 10th 2019

EP. 7: Liposomal Daunorubicin & Cytarabine for AML

January 10th 2019

EP. 8: MRD Status in AML

January 10th 2019

EP. 9: Maintenance Therapy for AML

January 10th 2019

EP. 10: Significance of FLT3 Mutations in AML

January 10th 2019

EP. 11: Midostaurin for FLT3-Mutant AML

January 10th 2019

EP. 12: Gilteritinib for FLT3-Mutant AML

January 10th 2019

EP. 13: Quizartinib for FLT3-Mutated AML

January 10th 2019

EP. 14: Resistance Mechanisms in AML and Treatment Decisions

January 10th 2019

EP. 15: IDH Inhibitors for AML

January 10th 2019

EP. 16: Immunotherapy for AML

January 10th 2019

EP. 17: Insight on Advances in the Treatment of AML

January 10th 2019